Onconetix, Inc. (ONCO)

Market Cap	1.24M -64.2%
Revenue (ttm)	735,198 -61.8%
Net Income	-10.03M
EPS	-300.31
Shares Out	1.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,063,861
Open	1.100
Previous Close	1.090
Day's Range	1.060 - 1.110
52-Week Range	0.911 - 269.995
Beta	2.72
Analysts	Hold
Price Target	1,530,000.77 (+141,666,637.96%)
Earnings Date	May 13, 2026

About ONCO

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Bl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 18, 2022
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCO
• Website: https://www.onconetix.com

Financial Performance

In 2025, Onconetix's revenue was $815,371, a decrease of -67.70% compared to the previous year's $2.52 million. Losses were -$15.53 million, -73.63% less than in 2024.

Analyst Summary

According to one analyst, the rating for ONCO stock is "Hold" and the 12-month stock price target is $1,530,000.77.

Price Target

$1,530,000.77

(141,666,637.96% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jun 17, 2026

Data Sources Report a data error